Aizen Therapeutics is pioneering the development of Mirror Peptides, which are synthetic peptides composed entirely of D-amino acids. These peptides represent a novel class of therapeutics that explore a previously untapped chemical space beyond naturally occurring peptides and proteins. Mirror Peptides are designed to offer enhanced therapeutic stability and reduced immunogenicity compared to existing treatment modalities, potentially leading to improved safety and efficacy for patients. Aizen is focusing on a range of indications, including neurological disorders, oncology, and genetic diseases, positioning Mirror Peptides as a next-generation targeting and delivery platform.

Central to Aizen's innovation is the DaX™ platform, developed by Caltech Professor David Van Valen. This first-in-class, structure-based protein design model utilizes advancements in Generative AI to analyze natural ligand-receptor datasets, enabling the creation of de novo Mirror Peptide structures that effectively bind to clinically relevant targets. The DaX™ platform employs cutting-edge techniques such as guided diffusion and computational binding models, achieving rapid design-build-test cycles of approximately four weeks, with hit rates surpassing current industry benchmarks. Its multi-objective optimization capabilities allow for the simultaneous enhancement of critical drug properties, including specificity, half-life, and solubility, thereby accelerating the drug development process.

United States

We are creating a new category of medicines with the application of spatial biology and AI.

Aizen Therapeutics

Company Details